<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04493554</url>
  </required_header>
  <id_info>
    <org_study_id>UESTC-neuSCAN-70</org_study_id>
    <nct_id>NCT04493554</nct_id>
  </id_info>
  <brief_title>The Effects of Vasopressin on Attention Control</brief_title>
  <official_title>The Effects of Vasopressin on Attention Control: An Eye-tracking Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Electronic Science and Technology of China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Electronic Science and Technology of China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of the present study is to investigate whether intranasal vasopressin (20IU)&#xD;
      could influence attention control in a social-emotional saccade/antisaccade eye-tracking&#xD;
      paradigm.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A number of previous studies have reported vasopressin's effect on human social behavior and&#xD;
      social cognition, although it remains unclear whether vasopressin could modulate attention&#xD;
      allocation including stimulus-driven bottom-up control and goal-directed top-down control. In&#xD;
      the current randomized, between-subject, placebo controlled study, 89 healthy male subjects&#xD;
      will be recruited and receive either vasopressin (20 IU) or placebo control administered&#xD;
      intranasally. 45 minutes after treatment subjects will be required to complete a&#xD;
      social-emotional saccade /antisaccade eye-tracking paradigm. The paradigm uses social (happy,&#xD;
      sad, angry, fear, and neutral faces) as well as non-social (oval shapes) stimuli to explore&#xD;
      social- and emotion-specific effects of vasopressin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 28, 2020</start_date>
  <completion_date type="Actual">January 1, 2021</completion_date>
  <primary_completion_date type="Actual">November 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Between-subject randomized placebo-controlled double-blind pharmacological eye-tracking design</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of vasopressin administration on saccade/antisaccade latencies towards social (facial) versus non-social (shape) stimuli</measure>
    <time_frame>45 minutes - 100 minutes after treatment</time_frame>
    <description>Comparison between social-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin and placebo treatment conditions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of vasopressin administration on error rates of saccade/antisaccade for social (facial) versus non-social (shape) stimuli</measure>
    <time_frame>45 minutes - 100 minutes after treatment</time_frame>
    <description>Comparison between social-specific error rates of saccade/antisaccade between the vasopressin and placebo treatment conditions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Emotion-specific effects of vasopressin administration on saccade/antisaccade latencies towards the separate facial emotions</measure>
    <time_frame>45 minutes - 100 minutes after treatment</time_frame>
    <description>Comparison between emotion-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin and placebo treatment conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emotion-specific effects of vasopressin administration on saccade/antisaccade error rates for the separate facial emotions</measure>
    <time_frame>45 minutes - 100 minutes after treatment</time_frame>
    <description>Comparison between emotion-specific saccade/antisaccade error rates between the vasopressin and placebo treatment conditions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Vasopressin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vasopressin (20 IU) intranasally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo intranasally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vasopressin</intervention_name>
    <description>Administration of vasopressin (20 IU) intranasally</description>
    <arm_group_label>Vasopressin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration of placebo intranasally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy participants&#xD;
&#xD;
          -  Non smokers&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous or current medical, psychiatric, neurological disorder&#xD;
&#xD;
          -  Regular medication&#xD;
&#xD;
          -  Use of any psychoactive substances in the 24 hours before experiment&#xD;
&#xD;
          -  Contra-indications for vasopressin&#xD;
&#xD;
          -  Contra-indications for eye-tracking data acquisition&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith Kendrick, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Electronic Science and Technology of China (UESTC)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Electronic Science and Technology of China(UESTC)</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>611731</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 27, 2020</study_first_submitted>
  <study_first_submitted_qc>July 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2020</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Electronic Science and Technology of China</investigator_affiliation>
    <investigator_full_name>Keith Kendrick</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

